Medicale Corp. (MCLE) Financial Statements (2026 and earlier)
Company Profile
| Business Address |
9314 FOREST HILL BLVD WELLINGTON, FL 33411 |
| State of Incorp. | NV |
| Fiscal Year End | September 30 |
| Industry (SIC) | 80 - Health Services (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) (USD)
| 12/31/2025 MRQ | 9/30/2025 | 9/30/2024 | 9/30/2023 | 9/30/2022 | 9/30/2021 | |||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash, cash equivalents, and short-term investments | 159 | 159 | 18,475 | |||||
| Cash and cash equivalent | 159 | 159 | 18,475 | |||||
| Receivables | 200 | |||||||
| Intangible current assets | 12,000 | |||||||
| Total current assets: | 159 | 159 | 12,000 | 18,675 | ||||
| Noncurrent Assets | ||||||||
| Intangible asset, including goodwill, after accumulated amortization | 7,200 | 9,600 | ||||||
| Intangible asset, excluding goodwill, after accumulated amortization | 7,200 | 9,600 | ||||||
| Total noncurrent assets: | 7,200 | 9,600 | ||||||
| TOTAL ASSETS: | 159 | 159 | 19,200 | 28,275 | ||||
| LIABILITIES AND EQUITY | ||||||||
| Liabilities | ||||||||
| Current Liabilities | ||||||||
| Accounts payable and accrued liabilities, including: | 10,644 | 25,000 | ||||||
| Accrued liabilities | 11,008 | |||||||
| Other undisclosed accounts payable and accrued liabilities | (364) | 25,000 | ||||||
| Disposal group, including discontinued operation | 12,000 | 12,000 | 12,000 | |||||
| Due to related parties | ✕ | ✕ | ✕ | ✕ | 17,774 | 11,630 | ||
| Other undisclosed current liabilities | 11,008 | 3,507 | 28,879 | 37,000 | ||||
| Total current liabilities: | 33,652 | 15,507 | 40,879 | 54,774 | 36,630 | |||
| Noncurrent Liabilities | ||||||||
| Long-term debt and lease obligation | 106,434 | 83,585 | ||||||
| Long-term debt, excluding current maturities | 106,434 | 83,585 | ||||||
| Total noncurrent liabilities: | 106,434 | 83,585 | ||||||
| Total liabilities: | 140,086 | 99,092 | 40,879 | 54,774 | 36,630 | |||
| Equity | ||||||||
| Equity, attributable to parent | (140,086) | (98,933) | (40,720) | (54,774) | (8,355) | |||
| Common stock | 592 | 592 | 592 | 592 | 592 | |||
| Additional paid in capital | 76,320 | 76,320 | 76,320 | 25,128 | 25,128 | |||
| Accumulated deficit | (216,998) | (175,845) | (117,632) | (80,494) | (34,075) | |||
| Total equity: | (140,086) | (98,933) | (40,720) | (54,774) | (8,355) | |||
| TOTAL LIABILITIES AND EQUITY: | 159 | 159 | 28,275 | |||||
Income Statement (P&L) (USD)
| 12/31/2025 TTM | 9/30/2025 | 9/30/2024 | 9/30/2023 | 9/30/2022 | 9/30/2021 | ||
|---|---|---|---|---|---|---|---|
| Operating expenses | (33,493) | (54,707) | (37,593) | (46,419) | (32,152) | ||
| Operating loss: | (33,493) | (54,707) | (37,593) | (46,419) | (32,152) | ||
| Nonoperating expense (Other Nonoperating expense) | (159) | ||||||
| Interest and debt expense | (7,501) | (3,506) | |||||
| Loss from continuing operations: | (41,153) | (58,213) | (37,593) | (46,419) | (32,152) | ||
| Loss before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | ✕ | (46,419) | (32,152) | |
| Income from discontinued operations | 455 | ||||||
| Other undisclosed net income | |||||||
| Net loss available to common stockholders, diluted: | (41,153) | (58,213) | (37,138) | (46,419) | (32,152) | ||
Comprehensive Income (USD)
| 12/31/2025 TTM | 9/30/2025 | 9/30/2024 | 9/30/2023 | 9/30/2022 | 9/30/2021 | ||
|---|---|---|---|---|---|---|---|
| Net loss: | (41,153) | (58,213) | (37,138) | (46,419) | (32,152) | ||
| Comprehensive loss, net of tax, attributable to parent: | (41,153) | (58,213) | (37,138) | (46,419) | (32,152) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.